Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; povidone; croscarmellose sodium; gelatin; indigo carmine; iron oxide red; iron oxide yellow - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; povidone; purified talc; titanium dioxide; croscarmellose sodium; macrogol 400; iron oxide red; iron oxide black; microcrystalline cellulose; magnesium stearate - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: gelatin; lactose; shellac; croscarmellose sodium; microcrystalline cellulose; indigo carmine; magnesium stearate; propylene glycol; potassium hydroxide; titanium dioxide; iron oxide black - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 10 mg - capsule - excipient ingredients: lactose; titanium dioxide; iron oxide yellow; gelatin; microcrystalline cellulose; croscarmellose sodium; propylene glycol; shellac; potassium hydroxide; magnesium stearate; indigo carmine; iron oxide black - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia,due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic,abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle,cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 5 mg - capsule - excipient ingredients: magnesium stearate; lactose; potassium hydroxide; propylene glycol; gelatin; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide black; shellac - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 25 mg - capsule - excipient ingredients: propylene glycol; croscarmellose sodium; titanium dioxide; lactose; gelatin; microcrystalline cellulose; iron oxide black; shellac; potassium hydroxide; magnesium stearate - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 35.1 mg (equivalent: sildenafil, qty 25 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; copovidone; microcrystalline cellulose; saccharin sodium; calcium hydrogen phosphate; croscarmellose sodium - sildenafil sandoz is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 140.4 mg (equivalent: sildenafil, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; copovidone; croscarmellose sodium; saccharin sodium; indigo carmine aluminium lake; calcium hydrogen phosphate; magnesium stearate - sildenafil sandoz is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - sildenafil sandoz is indicated for the treatment of erectile dysfunction in adult males. sildenafil sandoz is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose; purified talc; croscarmellose sodium - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.